Cadent Therapeutics

Cadent Therapeutics is creating breakthrough therapies for neurological and psychiatric conditions. The company is rapidly advancing a pipeline of novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory. Cadent’s first-of-its-kind approach has the potential to bring harmony back to neuronal rhythms, effectively “re-wiring” the brain to treat movement and cognitive disorders. In December 2020 Novartis acquired Cadent for up to $770 million.

Headquarters Cambridge, MA
Pipeline Phase 2
Partners Novartis
Twitter @CadentTx​